$2,293.03 general Payment -- AstraZeneca to Dr. Patricia Davis
AstraZeneca payment to Nephrologist Patricia Davis for Ocrevus education in Alabama
This page provides a detailed analysis of a $2,293.03 general payment from AstraZeneca to Dr. Patricia Davis. Data is from the CMS Open Payments (Sunshine Act) database.
Payment Details
| Field | Value |
|---|---|
| Amount | $2,293.03 |
| Payment Type | general |
| Payment Nature | Education |
| Pharmaceutical Company | AstraZeneca |
| Physician | Dr. Patricia Davis |
| NPI Number | 1385032552 |
| Physician Specialty | Nephrology |
| Location | City, AL |
| Date of Payment | 2024-04-16 |
| Related Drug/Device | Ocrevus |
| Conflict Assessment | Moderate -- Worth Noting |
AI-Powered Analysis of This Payment
The following analysis was generated by artificial intelligence to help patients understand the context, significance, and implications of this pharmaceutical payment. This analysis is not medical or legal advice.
AstraZeneca made a $2.3K general payment to Patricia Davis, a Nephrology specialist in City, AL. The payment was associated with Ocrevus. The payment of $2,293.03 to Dr. Patricia Davis from AstraZeneca for educational purposes related to Ocrevus is a notable transaction. This payment falls under the 'general' payment type and 'Education' nature, indicating it's likely for informational or training activities. The specific drug mentioned, Ocrevus, is often associated with autoimmune diseases, and its use in Nephrology warrants attention.
Patient Guidance: What This Payment Means for You
If you are a patient receiving Ocrevus, understand that your doctor may receive educational payments from pharmaceutical companies to stay informed about treatments. Always discuss your treatment options with your healthcare provider and ask about alternatives.
Payment Context: Is This Amount Normal?
Payments for educational purposes in Nephrology can vary widely depending on the nature of the education and the specialty's engagement with specific drugs.
Regulatory Context: Sunshine Act Requirements
This payment is subject to reporting requirements under the Physician Payments Sunshine Act, part of the Affordable Care Act, which mandates transparency in financial relationships between drug manufacturers and healthcare providers.
Related Topics
This payment is related to the following healthcare transparency topics:
- pharma-payments
- nephrology
- drug-education
- astrazeneca
- ocrevus
- cms-open-payments
Understanding general Payments
general payments are one of several categories of financial transfers from pharmaceutical and medical device companies to physicians that must be reported under the Sunshine Act. Understanding the type and context of a payment is important for evaluating its significance. Not all payments are equal -- a research grant has very different implications than a promotional speaking fee.
Frequently Asked Questions About This Payment
What was this $2.3K payment for?
This was a general payment of $2.3K from AstraZeneca to Patricia Davis, categorized as "Education". It was associated with Ocrevus. The payment was reported under the Sunshine Act (CMS Open Payments).
Does Patricia Davis accept pharmaceutical money?
Yes, Patricia Davis received this $2.3K payment from AstraZeneca. Under the Sunshine Act, pharmaceutical companies must report all payments to physicians exceeding $10. You can view Patricia Davis's full payment history on the CMS Open Payments database or on this site.
Is it legal for doctors to accept pharma payments?
Yes, it is legal for physicians to receive payments from pharmaceutical companies. The Physician Payments Sunshine Act (2010) requires transparency by mandating that companies report all payments exceeding $10 to CMS. These payments include consulting fees, meals, travel, speaking fees, and research grants. The law does not prohibit payments but ensures public disclosure.
Should I be concerned about this general payment?
A general payment of $2.3K should be evaluated in context. Payment does not imply wrongdoing, but patients have the right to ask their doctor about pharmaceutical relationships.
How do I talk to my doctor about pharma relationships?
You can ask your doctor directly: "Do you receive payments from pharmaceutical companies?" and "Does this affect which medications you prescribe?" Most doctors will answer honestly. You can also verify payment data yourself through CMS Open Payments (openpaymentsdata.cms.gov). Consider asking about generic alternatives and whether the prescribed medication is the best option regardless of manufacturer relationships.
What types of pharma payments are most concerning?
Ownership interests and large consulting/speaking fees are generally considered more significant than meals or small educational grants. Research payments typically fund clinical studies and are common in academic medicine. The total volume and concentration of payments from a single company may be more telling than any individual payment. Patterns matter more than individual transactions.
Does pharma money affect what my doctor prescribes?
Research shows that even small payments can influence prescribing behavior. Studies published in JAMA Internal Medicine found that physicians who received meals costing as little as $20 were more likely to prescribe the promoted brand-name drug. However, many physician-industry interactions are legitimate professional activities. The key is transparency and awareness.
How does this compare to other doctors in Nephrology?
To compare this payment against Nephrology averages, check the full specialty breakdown on CMS Open Payments. Payment amounts vary widely by specialty and type. Nephrology physicians may receive payments for consulting, speaking, or research that are standard for the field. Individual payments should be evaluated in the context of the doctor's full payment history.
What does this payment reveal about Patricia Davis's relationship with AstraZeneca?
The payment amount is specific, suggesting a defined educational program or event. This $2.3K general payment is part of the transparency data reported under the Sunshine Act.
Is this payment amount typical for Nephrology?
The date of payment is recent, falling within 2024.
What should patients do after learning about this payment?
If you are a patient receiving Ocrevus, understand that your doctor may receive educational payments from pharmaceutical companies to stay informed about treatments.
What else should I know about this general payment?
The NPI number provides a unique identifier for Dr. Davis.
Related Reports
Data from CMS Open Payments. Payment does not imply wrongdoing. Consult your healthcare provider about any concerns.